

Current Treatment Options for Osteoarthritis

This supplement to *The American Journal of Managed Care* reviews the economic and clinical implications of osteoarthritis, as well as current treatment options.

■ Participating Faculty

Roy Davis Altman, MD

Professor of Medicine
Division of Rheumatology and Immunology
David Geffen School of Medicine
University of California Los Angeles
Los Angeles, California

Ryan Bitton, PharmD, MBA

Manager, Pharmacy Services
Health Plan of Nevada, Inc.
Las Vegas, Nevada

Roland W. Moskowitz, MD

Clinical Professor
Department of Medicine
Case Western Reserve University
Cleveland, Ohio

■ Faculty Disclosures

Roy Davis Altman, MD

Consultant:

Endo
Ferring
Novartis

Research Grants:

Ferring
Novartis

Lecturer:

Ferring
Forest

Ryan Bitton, PharmD, MBA, and **Roland W. Moskowitz, MD**, have nothing to disclose.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

Current Treatment Options for Osteoarthritis

Funding

This supplement has been supported by funding from **Endo Pharmaceuticals**.

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.